Rosiglitazone and PPAR-γ overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins

Journal of Cellular Physiology

Volumn 220, Issue 1, 2009, Pages 58-71

  Wu, Jui Sheng ^a,b   Lin, Teng Nan ^b   Wu, Kenneth K ^c,d  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; CASPASE 3; CASPASE 9; CYTOCHROME C; HYDROGEN PEROXIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; ROSIGLITAZONE; SMALL CYTOPLASMIC RNA; SMALL INTERFERING RNA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2-CHLORO-5-NITROBENZANILIDE; 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE; 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE; ANILIDE; BAD PROTEIN, MOUSE; BCL2L1 PROTEIN, MOUSE; CASP3 PROTEIN, MOUSE; CASP9 PROTEIN, MOUSE; GLUCOSE; PROTEIN BCL X; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; GENE OVEREXPRESSION; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; REOXYGENATION; UPREGULATION; ANIMAL; CELL HYPOXIA; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; NEUROBLASTOMA; PATHOLOGY; PHOSPHORYLATION; REPERFUSION INJURY; RNA INTERFERENCE; TIME; TUMOR CELL LINE;

ANILIDES; ANIMALS; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; BCL-X PROTEIN; CASPASE 3; CASPASE 9; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; CYTOCHROMES C; CYTOPROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; HYDROGEN PEROXIDE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MITOCHONDRIA; NEUROBLASTOMA; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PPAR GAMMA; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; REPERFUSION INJURY; RNA INTERFERENCE; RNA, SMALL INTERFERING; THIAZOLIDINEDIONES; TIME FACTORS; TRANSFECTION; UP-REGULATION;

EID: 65549166721     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21730     Document Type: Article

References (32)

1. Baker PR, Lin Y, Schopfer FJ, Woodcock SR, Groeger AL, Batthyany C, Sweeney S, Long MH, Iles KE, Baker LM, Branchaud BP, Chen YE, Freeman BA. 2005. Fatty acid transduction of nitric oxide signaling: Multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands. J Biol Chem 280:42464-42475.
2. Bell-Parikh LC, Ide T, Lawson JA, McNamara P, Reilly M, FitzGerald GA. 2003. Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. J Clin Invest 112:945-955.
3. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. 2001. PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7:48-52.
4. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. 1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91:231-241.
5. Deng WG, Zhu Y, Wu KK. 2004. Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood 103:2135-2142.
6. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 83:803-812.
7. Fuenzalida K, Quintanilla R, Ramos P, Piderit D, Fuentealba RA, Martinez G, Inestrosa NC, Bronfman M. 2007. Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J Biol Chem 282:37006-37015.
8. Goldberg MP, Choi DW. 1993. Combined oxygen and glucose deprivation in cortical cell culture: Calcium-dependent and calcium-independent mechanisms of neuronal injury. J Neurosci 13:3510-3524.
9. Hengartner MO. 2000. The biochemistry of apoptosis. Nature 407:770-776.
10. Hu CJ, Chen SD, Yang DI, Lin TN, Chen CM, Huang TH, Hsu CY. 2006. Promoter region methylation and reduced expression of thrombospondin-1 after oxygen-glucose deprivation in murine cerebral endothelial cells. J Cereb Blood Flow Metab 26:1519-1526.
11. Jiang C, Ting AT, Seed B. 1998. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86.
12. Jung TW, Lee JY, Shim WS, Kang ES, Kim SK, Ahn CW, Lee HC, Cha BS. 2007. Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production. J Neurol Sci 253:53-60.
13. Kliewer SA, Lenhard JM, Willson TM, Patel L, Morris DC, Lehmann JM. 1995. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83:813-819.
14. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor-γ (PPAR-γ). J Biol Chem 270:12953-12956.
15. Lim S, Jin CJ, Kim M, Chung SS, Park HS, Lee IK, Lee CT, Cho YM, Lee HK, Park KS. 2006. PPARgamma gene transfer sustains apoptosis, inhibits vascular smooth muscle cell proliferation, and reduces neointima formation after balloon injury in rats. Arterioscler Thromb Vasc Biol 26:808-813.
16. Lin CY, Gurlo T, Haataja L, Hsueh WA, Butler PC. 2005. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′-kinase-dependent pathway. J Clin Endocrinol Metab 90:6678-6686.
17. Lin TN, Cheung WM, Wu JS, Chen JJ, Lin H, Chen JJ, Liou JY, Shyue SK, Wu KK. 2006. 15d-Prostaglandin J2 protects brain from ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol 26:481-487.
18. Liou JY, Lee S, Ghelani D, Matijevic-Aleksic N, Wu KK. 2006. Protection of endothelial survival by peroxisome proliferator-activated receptor-δ mediated 14-3-3 upregulation. Arterioscler Thromb Vasc Biol 26:1481-1487.
19. Liu HR, Tao L, Gao E, Lopez BL, Christopher TA, Willette RN, Ohlstein EH, Yue TL, Ma XL. 2004. Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res 62:135-144.
20. Pérez-Ortiz JM, Tranque P, Vaquero CF, Domingo B, Molina F, Calvo S, Jordán J, Ceña V, Llopis J. 2004. Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma. J Biol Chem 279:8976-8985.
21. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. 1998. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391:79-82.
22. Schopfer FJ, Lin Y, Baker PR, Cui T, Garcia-Barrio M, Zhang J, Chen K, Chen YE, Freeman BA. 2005. Nitrolinoleic acid: An endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci USA 102:2340-2345.
23. Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW, Chen CS. 2005. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res 65:1561-1569.
24. Shimazu T, Inoue I, Araki N, Asano Y, Sawada M, Furuya D, Nagoya H, Greenberg JH. 2005. A peroxisome proliferator-activated receptor-g agonist reduces infarct size in transient but not in permanent ischemia. Stroke 36:353-359.
25. Sundararajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE. 2005. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 130:685-696.
26. Wang YL, Frauwirth KA, Rangwala SM, Lazar MA, Thompson CB. 2002. Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival. J Biol Chem 277:31781-31788.
27. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. 2003. PPAR-γ and PPAR-δ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages. Proc Natl Acad Sci USA 100:6712-6717.
28. Willson TM, Lambert MH, Kliewer SA. 2001. Peroxisome proliferator- activated receptor-γ and metabolic disease. Annu Rev Biochem 70:341-367.
29. Youle RJ, Strasser A. 2008. The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9:47-59.
30. Yue TL, Chen J, Bao W, Narayanan PK, Bril A, Jiang W, Lysko PG, Gu JL, Boyce R, Zimmerman DM, Hart TK, Buckingham RE, Ohlstein EH. 2001. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Circulation 104:2588-2594.
31. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. 1996. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 Not BCL-XL. Cell 87:619-628.
32. Zha J, Harada H, Osipov K, Jockel J, Waksman G, Korsmeyer SJ. 1997. BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity. J Biol Chem 272:24101-24104.